Open Access
Subscription Access
Open Access
Subscription Access
Pharmacodynamic Drug Interaction of Ethionamide with Glibenclamide in Normal and Diabetic Rats
Subscribe/Renew Journal
The present study was aimed to find out the effect of treatment of ethionamide, an antitubercular drug on hypoglycaemic activity of glibenclamide in normal and diabetic rats. The study was intended to determine the pharmacodynamic parameters of drug interaction between glibenclamide and ethionamide in normal and diabetic rats. The studies were conducted using six group of normal adult rats of either sex. They were treated with half therapeutic dose of ethionamide (0.18 mg/200 g), therapeutic dose of ethionamide (0.36 mg/200 g), double therapeutic dose of ethionamide (0.72 mg/200 g), therapeutic dose of glibenclamide (0.18 mg/200 g) and combination of therapeutic dose of ethionamide and glibenclamide (0.36 mg/200 g + 0.18 mg/200 g).
Another group of six rats were taken and diabetes was induced by administering alloxan at a dose of 100 mg/ kg body weight intraperitoneally. Rats with glucose levels more than 200 mg/dL were considered for studied.
The blood samples were collected from tail vein at predetermined time intervals and blood glucose level was estimated using GOD/POD method with the aid of ARTOS semi auto analyser. Ethionamide produced hypoglycaemia when administered alone. The results indicated that in both normal as well as in diabetic rats ethionamide treatment altered the hypoglycaemic activity when administerd along with glibenclamide. This may be due to the synergistic effect of ethionamide with glibenclamide. The preliminary study indicate the combination may be unsafe in diabetes associated with tuberculosis.
Keywords
- Shorvon SD, Reynolds EH. Unnecessary polypharmacy for epilepsy. Br. Med J 197; 1635-37.
- Steel KK, Gertman PM, Gresienze C, Andersen J. Iatrogenic illness on a general medical service at a university hospital. N Eng J Med 1981; 34: 638-42.
- King H, Aubert KE, Herman WH. Global burden of diabetes 1995-2025. Prevalence, numerical estimate and protection. Diabetes care 1998; 2: 1414-31.
- Songer TJ, Zimmet PZ. Epidemology of type II diabetes on international perspective, pharmacomeyrics 8 (supl.): 1995; 1- 11.
- World Health Organization. Global tuberculosis control: 2010 Geneva: World Health Organization; 2010.
- Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th Ed. Edinburg: Churchill Livingstone; 2003.
- Patel JC. Complications in 8793 cases of diabetes mellitus 14 years study in Bombay hospital, India. Ind I. Med. Sci. 1989, 43, 177.
- Ezung T, Devi NT, Singh TB. Pulmonary tuberculosis and diabetes mellitus- a study. J. of Indian Medical Association. 2002, 100, 316.
- Goswami R, Kochupillai N. Endocrine implication of tuberculosis. In: Sharma SK, Mohan A (Eds). Tuberculosis. New Delhi: Jaypee Brothers Medical publishers (P) Ltd., 2001, 386.
- Mboussa J, Monabeka H, Kombo M, Yokolo D, Yoka- Mbio A, Yala F. Course of tuberculosis in diabetics. Rev. pneumol clin. 2003, 359, 36.
- Bhatia JL, Lal H. (1966). Indian J. Tnberc. 13, 57.
- Laurence DR, Bacharach AL. Evaluation of drug activities and pharmacometrics. London and New York: Academic Press; 1964.
- Trinder P. Ann Clin Biochem 1964; 6: 24.
- Goldhaber-Fiebert JD, Jeon CY, Cohen T, et al. Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. Int J Epidemiol 2011; 40 (2): 417-428.
- World Health Organization. Tuberculosis and diabetes. Collaborative Framework for care and control of tuberculosis and diabetes. WHO sept. 2011. www.who.int/td.
Abstract Views: 357
PDF Views: 1